NeuroPace Inc

NeuroPace, Inc. is a medical device company that aims to improve the lives of individuals with epilepsy by reducing or eliminating seizures. The company's primary product is the RNS System, a brain-responsive neuromodulation system. This system is designed to provide personalized, real-time treatment at the source of seizures. It works by continuously monitoring and analyzing the brain's electrical activity, identifying patient-specific abnormal electrical patterns, and responding with electrical pulses to prevent seizures. Clinicians program the RNS System to deliver precise therapy, resulting in approximately three minutes of stimulation on average per day. The RNS System is also the only commercially available device that records continuous brain activity data, enabling clinicians to monitor patients both in person and remotely. This data helps clinicians make more informed treatment decisions. As of December 31, 2025, over 8,000 patients have received the RNS System. The company targets the approximately 575,000 adults in the United States with drug-resistant focal epilepsy and seeks to expand its indication to cover the entire approximately 1.2 million drug-resistant epilepsy patients in the United States. NeuroPace may also expand globally to reach the approximately 16.5 million drug-resistant epilepsy patients worldwide. Epilepsy is a chronic disorder where the brain produces abnormal electrical bursts causing seizures, and treatment aims to reduce seizure frequency and intensity without side effects.